SY23-4 Combination therapy with immune checkpoint inhibitor and targeted agents in metastatic TNBC and HR-positive breast cancer

Abstract

In recent years, immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) pathway have been developed for various cancer types. The IMpassion 130 study demonstrated the efficacy and safety of atezolizumab, a programmed cell death ligand-1 (PD-L1) antibody, plus nab-paclitaxel for patients with PD-L1-positive triple-negative breast cancer (TNBC). However, IMpassion 131 study did not demonstrate the efficacy of atezolizumab plus paclitaxel for patients with PD-L1-positive TNBC. Now the discussion of optimal combination strategy is getting more interesting and challenging. On the other hand, hormone receptor-positive BC and PD-L1-negative TNBC are less sensitive than PD-L1-positive TNBC to immune checkpoint inhibitors. Novel combinations of multiple classes of drugs are under evaluation. Anti-VEGF antibody or in combination with PD-1 antibody is evaluated in various cancer types, and the strategy is also promising in hormone receptor-positive BC and PD-L1-negative TNBC. Combination therapy of CDK4/6 inhibitor and PD-1/L-1 antibody is also a potential strategy in hormone receptor(HR)-positive, HER2-negative metastatic BC. We discuss future perspective of immunotherapy in combination with targeted agents in metastatic TNBC and also HR-positive breast cancer.